1. Home
  2. BEAM vs SBLK Comparison

BEAM vs SBLK Comparison

Compare BEAM & SBLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$34.32

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Star Bulk Carriers Corp.

SBLK

Star Bulk Carriers Corp.

HOLD

Current Price

$24.18

Market Cap

2.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
SBLK
Founded
2017
2006
Country
United States
Greece
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.9B
IPO Year
2019
2007

Fundamental Metrics

Financial Performance
Metric
BEAM
SBLK
Price
$34.32
$24.18
Analyst Decision
Buy
Strong Buy
Analyst Count
12
2
Target Price
$50.75
$25.50
AVG Volume (30 Days)
2.1M
1.2M
Earning Date
05-06-2026
05-20-2026
Dividend Yield
N/A
2.33%
EPS Growth
82.31
N/A
EPS
N/A
N/A
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$11.56
Revenue Next Year
$33.77
N/A
P/E Ratio
N/A
$47.06
Revenue Growth
33.33
N/A
52 Week Low
$15.60
$16.72
52 Week High
$36.88
$28.50

Technical Indicators

Market Signals
Indicator
BEAM
SBLK
Relative Strength Index (RSI) 59.75 33.84
Support Level $26.96 $23.88
Resistance Level $36.44 $27.81
Average True Range (ATR) 2.18 0.82
MACD 0.34 -0.30
Stochastic Oscillator 68.09 12.45

Price Performance

Historical Comparison
BEAM
SBLK

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About SBLK Star Bulk Carriers Corp.

Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. The firm generates the majority of its revenue from Time charters and Voyage charters.

Share on Social Networks: